Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection.

Schott E, Witt H, Hinrichsen H, Neumann K, Weich V, Bergk A, Halangk J, Müller T, Tinjala S, Puhl G, Neuhaus P, Wiedenmann B, Berg T.

J Hepatol. 2007 Mar;46(3):372-80. Epub 2006 Nov 2.

PMID:
17150279
2.

Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection.

Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA.

J Infect Dis. 2003 Apr 15;187(8):1264-71. Epub 2003 Apr 2.

PMID:
12696006
3.

Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease.

Schott E, Witt H, Pascu M, van Boemmel F, Weich V, Bergk A, Halangk J, Müller T, Puhl G, Wiedenmann B, Berg T.

Eur J Gastroenterol Hepatol. 2007 Nov;19(11):947-51.

PMID:
18049163
4.

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.

Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, Renda MC, Pitrolo L, Lo Pinto MC, Rizzo M, Fiorenza F, Gerardi C, Grimaudo S, Di Cristina A, Levrero M, Craxì A.

Haematologica. 2012 May;97(5):679-86. doi: 10.3324/haematol.2011.050351. Epub 2011 Dec 16.

5.

IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.

Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar-Olivos N, Madrid-Marina V, Román-Bahena M, Orbe-Orihuela C, Misael U, Méndez-Sánchez N.

Ann Hepatol. 2012 Nov-Dec;11(6):876-81.

6.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
7.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

9.
10.

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV.

Gastroenterology. 2000 Feb;118(2):346-55.

PMID:
10648463
11.

Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study.

Peng CY, Chen TH, Lim YP, Tsai FJ, Lin WY, Liao WL, Wan L.

BMC Gastroenterol. 2014 Jun 26;14:113. doi: 10.1186/1471-230X-14-113.

12.

Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.

Rumi MG, Aghemo A, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M.

Antivir Ther. 2007;12(7):1033-40.

PMID:
18018761
13.

Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.

Lunel F, Veillon P, Fouchard-Hubert I, Loustaud-Ratti V, Abergel A, Silvain C, Rifflet H, Blanchi A, Causse X, Bacq Y, Payan C; Fontevraud Study Group.

J Hepatol. 2003 Nov;39(5):826-33.

PMID:
14568267
14.

Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.

Aghemo A, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M.

Antivir Ther. 2006;11(6):797-802.

PMID:
17310824
15.

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P.

J Viral Hepat. 2003 Jan;10(1):37-42.

PMID:
12558910
16.

Association of polymorphisms in the first exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection.

Segat L, Silva Vasconcelos LR, Montenegro de Melo F, Santos Silva B, Arraes LC, Moura P, Crovella S.

Clin Immunol. 2007 Jul;124(1):13-7. Epub 2007 May 21.

PMID:
17513174
17.

Associations between cytotoxic T lymphocyte-associated antigen-4 polymorphisms and serum tumor necrosis factor-α and interferon-γ levels in patients with chronic hepatitis B virus infection.

Han Q, Duan S, Zhang G, Li Z, Li N, Zhu Q, Lv Y, Chen J, Liu Z.

Inflamm Res. 2011 Nov;60(11):1071-8. doi: 10.1007/s00011-011-0368-8. Epub 2011 Aug 17.

PMID:
21847627
18.

Cytotoxic T-lymphocyte-associated antigen-4 single nucleotide polymorphisms and haplotypes in primary biliary cirrhosis.

Donaldson P, Veeramani S, Baragiotta A, Floreani A, Venturi C, Pearce S, Wilson V, Jones D, James O, Taylor J, Newton J, Bassendine M.

Clin Gastroenterol Hepatol. 2007 Jun;5(6):755-60. Epub 2007 May 7.

PMID:
17482523
19.

Co-stimulatory molecule CD80 expression may correlate with anti-HCV treatment outcome.

Sacchi A, Agrati C, D'Offizi G, Vlassi C, Martini F.

Gut. 2011 Aug;60(8):1161-2. doi: 10.1136/gut.2010.210765. Epub 2010 Aug 30. No abstract available.

PMID:
20805310
20.

CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection.

Hoare M, Gelson WT, Das A, Fletcher JM, Davies SE, Curran MD, Vowler SL, Maini MK, Akbar AN, Alexander GJ.

J Hepatol. 2010 Aug;53(2):252-60. doi: 10.1016/j.jhep.2010.03.005. Epub 2010 Apr 22.

Supplemental Content

Support Center